TG Therapeutics challenges Roche with FDA filing for CLL drug
pharmaphorum
DECEMBER 2, 2020
US biotech TG Therapeutics has begun a rolling filing with the FDA for its combination therapy for chronic lymphocytic leukaemia, in a challenge to Roche. The trial continued enrolment in a 1:1 ratio into the two combination arms: the investigational arm of U2 and the control arm of obinutuzumab plus chlorambucil.
Let's personalize your content